GR3019768T3 - N-substituted imidazol-2-one compounds for treatment of circulatory disorders - Google Patents

N-substituted imidazol-2-one compounds for treatment of circulatory disorders

Info

Publication number
GR3019768T3
GR3019768T3 GR960401028T GR960401028T GR3019768T3 GR 3019768 T3 GR3019768 T3 GR 3019768T3 GR 960401028 T GR960401028 T GR 960401028T GR 960401028 T GR960401028 T GR 960401028T GR 3019768 T3 GR3019768 T3 GR 3019768T3
Authority
GR
Greece
Prior art keywords
butyl
compounds
image
treatment
phenethyl
Prior art date
Application number
GR960401028T
Other languages
English (en)
Inventor
David B Reitz
Robert E Manning
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Publication of GR3019768T3 publication Critical patent/GR3019768T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GR960401028T 1990-10-31 1996-04-25 N-substituted imidazol-2-one compounds for treatment of circulatory disorders GR3019768T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/606,806 US5087634A (en) 1990-10-31 1990-10-31 N-substituted imidazol-2-one compounds for treatment of circulatory disorders
PCT/US1991/007729 WO1992007834A1 (en) 1990-10-31 1991-10-28 N-substituted imidazol-2-one compounds for treatment of circulatory disorders

Publications (1)

Publication Number Publication Date
GR3019768T3 true GR3019768T3 (en) 1996-07-31

Family

ID=24429549

Family Applications (1)

Application Number Title Priority Date Filing Date
GR960401028T GR3019768T3 (en) 1990-10-31 1996-04-25 N-substituted imidazol-2-one compounds for treatment of circulatory disorders

Country Status (12)

Country Link
US (1) US5087634A (el)
EP (1) EP0555331B1 (el)
AT (1) ATE137226T1 (el)
AU (1) AU8867291A (el)
CA (1) CA2094390C (el)
DE (1) DE69119089T2 (el)
DK (1) DK0555331T3 (el)
ES (1) ES2086003T3 (el)
GR (1) GR3019768T3 (el)
IE (1) IE913814A1 (el)
PT (1) PT99392B (el)
WO (1) WO1992007834A1 (el)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270317A (en) * 1990-03-20 1993-12-14 Elf Sanofi N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
CA2058198A1 (en) * 1991-01-04 1992-07-05 Adalbert Wagner Azole derivatives, process for their preparation, and their use
US5187271A (en) * 1991-02-28 1993-02-16 G. D. Searle & Co. N-substituted (α-imidazolyl-toluyl) pyrrole compounds for treatment of circulatory disorders
US6008368A (en) * 1993-04-28 1999-12-28 G. D. Searle & Co. Pharmaceutical compositions for treatment of circulatory disorders using N-substituted (α-imidazolyl-toluyl) pyrrole aniotensin II antagonists
US5164403A (en) * 1991-04-05 1992-11-17 G. D. Searle & Co. N-arylheteroarylalkyl imidazol-2-one compounds for treatment of circulatory disorders
US5861420A (en) * 1991-04-05 1999-01-19 G. D. Searle & Co. N-arylheteroarylalkyl imidazol-2-one compounds for treatment of circulatory disorders
PH30449A (en) * 1991-11-25 1997-05-28 Lilly Co Eli Substituted phenyl phenol leukotriene antagonists
US5663053A (en) * 1992-02-11 1997-09-02 Smithkline Beecham Corporation Inhibition of inflammatory lipid mediators
WO1993016674A1 (en) * 1992-02-11 1993-09-02 Smithkline Beecham Corporation CoA-IT AND PAF INHIBITORS
AU666705B2 (en) * 1992-02-13 1996-02-22 Warner-Lambert Company rocess for preparing chiral ethyl (5-amino-1,2-dihydro-2-methyl-3-phenylpyrido(3,4-b)pyrazin-7 -yl)carbamate
TW215434B (el) * 1992-03-07 1993-11-01 Hoechst Ag
US5972990A (en) * 1992-04-10 1999-10-26 Brigham And Women's Hospital, Inc. Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims
EP0664802B1 (en) * 1992-10-13 2000-03-15 G.D. Searle & Co. N-arylheteroarylalkyl 1-phenyl-imidazol-2-one compounds for treatment of circulatory disorders
CA2143192A1 (en) * 1992-10-13 1994-04-28 David B. Reitz N-arylheteroarylalkyl 1-cycloalkyl-imidazol-2-one compounds for treatment of circulatory disorders
WO1994021629A1 (en) * 1993-03-24 1994-09-29 G.D. Searle & Co. 1-phenyl-imidazol-2-one biphenylmethyl compounds for treatment of circulatory disorders
DE4317321A1 (de) * 1993-05-25 1994-12-01 Bayer Ag Substituierte 2,4-Imidazolidindione
US5451597A (en) * 1993-05-27 1995-09-19 G.D. Searle & Co. Treatment of circulatory disorders using n-substituted (α-imidazolyl-toluyl) pyrrole angiotensin II antagonists
EP0685467A4 (en) * 1993-12-16 1996-04-17 Nippon Kokan Kk PYRIMID DERIVATIVES AND MEDICAL PREPARATION.
SE9903028D0 (sv) 1999-08-27 1999-08-27 Astra Ab New use
JP2003509478A (ja) * 1999-09-21 2003-03-11 エモリー・ユニバーシティ 血小板関連障害を処置する方法および組成物
DE60138535D1 (de) 2000-02-04 2009-06-10 Children S Hospital Res Founda Verwendung von lysosomal acid lipase zur behandlung von atherosklerose und ähnlichen krankheiten
JP4514606B2 (ja) 2002-05-09 2010-07-28 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド 心血管疾患マーカーおよび治療標的としてのｉｌ１ｒｌ−１
SI2384753T1 (sl) 2003-08-29 2016-06-30 The Brigham And Women's Hospital, Inc. Hidantoinski derivati kot inhibitorji celične nekroze
EP2306192B1 (en) 2003-12-05 2015-10-14 The Cleveland Clinic Foundation Risk Markers For Cardiovascular Disease
US7803838B2 (en) * 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
DK1809759T3 (da) 2004-10-06 2014-01-06 Brigham & Womens Hospital Relevans af opnåede niveauer af markører for systemisk inflammation efter behandling
AP2764A (en) * 2005-01-31 2013-09-30 Mylan Lab Inc Hydroxylated nebivolol metabolites
AU2005332300B2 (en) 2005-05-31 2011-07-07 Mylan Laboratories, Inc. Compositions comprising nebivolol
US20090297496A1 (en) * 2005-09-08 2009-12-03 Childrens Hospital Medical Center Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases
US8119358B2 (en) * 2005-10-11 2012-02-21 Tethys Bioscience, Inc. Diabetes-related biomarkers and methods of use thereof
US20080057590A1 (en) * 2006-06-07 2008-03-06 Mickey Urdea Markers associated with arteriovascular events and methods of use thereof
ES2434215T3 (es) 2007-04-18 2013-12-16 Tethys Bioscience, Inc. Biomarcadores relacionados con la diabetes y métodos de uso de los mismos
AU2008261102B2 (en) 2007-06-04 2013-11-28 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US7828840B2 (en) * 2007-11-15 2010-11-09 Med Institute, Inc. Medical devices and methods for local delivery of angiotensin II type 2 receptor antagonists
CA2930674A1 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
GB2460915B (en) 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
JP2011528375A (ja) 2008-07-16 2011-11-17 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
TW201201764A (en) 2010-02-01 2012-01-16 Hospital For Sick Children Remote ischemic conditioning for treatment and prevention of restenosis
KR20190000368A (ko) 2010-03-31 2019-01-02 더 호스피탈 포 식 칠드런 심근 경색 후 결과를 개선시키기 위한 원격 허혈 처치의 사용
WO2011127341A2 (en) 2010-04-08 2011-10-13 The Hospital For Sick Children Use of remote ischemic conditioning for traumatic injury
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
PL2734222T3 (pl) 2011-07-18 2017-03-31 Critical Care Diagnostics, Inc. Sposoby leczenia chorób układu krążenia i prognozowania skuteczności terapii ruchowej
NZ701702A (en) 2012-05-11 2017-07-28 Reset Therapeutics Inc Carbazole-containing sulfonamides as cryptochrome modulators
AU2013296803B2 (en) 2012-08-01 2018-03-08 Eric Ostertag Free flowing, frozen compositions comprising a therapeutic agent
JP2016514670A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
WO2014145022A1 (en) 2013-03-15 2014-09-18 President And Fellows Of Harvard College Hybrid necroptosis inhibitors
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
JP6606491B2 (ja) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃの超高純度アゴニスト、その作成および使用方法
TWI690521B (zh) 2014-04-07 2020-04-11 美商同步製藥公司 作為隱花色素調節劑之含有咔唑之醯胺類、胺基甲酸酯類及脲類

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE160447C (el) *
BE621842A (el) * 1962-08-27
IT1052119B (it) * 1972-10-16 1981-06-20 Sigma Tau Ind Farmaceuti Derivati del triazolinone e procedimento per la loro preparazione
AU4806979A (en) * 1978-06-15 1979-12-20 Beecham Group Limited 1,2,4 triazole derivatives
DK117986A (da) * 1985-03-16 1986-09-17 Wellcome Found Arylderivater, fremgangsmaader til deres fremstilling og deres anvendelse
US4677131A (en) * 1985-11-01 1987-06-30 Merck & Co., Inc. Cyclic ureas as dermal penetration enhancers
US4816463A (en) * 1986-04-01 1989-03-28 Warner-Lambert Company Substituted diimidazo [1,5-a: 4',5'-d]pyridines having antihypertensive activity
CA1334092C (en) * 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US5028610A (en) * 1987-03-18 1991-07-02 Sankyo Company Limited N-benzhydryl-substituted heterocyclic derivatives, their preparation and their use
US5015651A (en) * 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
US4880804A (en) * 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles
DE69024556T2 (de) * 1989-07-28 1996-10-17 Merck & Co Inc Substituierte Triazolinone, Triazolinthione und Triazolinimine als Angiotensin II-Antagonisten
FR2659967B1 (fr) * 1990-03-20 1992-07-24 Sanofi Sa Derives d'imidazolinone n-substitues, leur preparation, les compositions pharmaceutiques en contenant.

Also Published As

Publication number Publication date
DE69119089D1 (de) 1996-05-30
DK0555331T3 (da) 1996-05-13
EP0555331A1 (en) 1993-08-18
PT99392B (pt) 1999-04-30
EP0555331B1 (en) 1996-04-24
ES2086003T3 (es) 1996-06-16
CA2094390A1 (en) 1992-05-01
WO1992007834A1 (en) 1992-05-14
CA2094390C (en) 2002-01-29
DE69119089T2 (de) 1996-10-17
ATE137226T1 (de) 1996-05-15
US5087634A (en) 1992-02-11
AU8867291A (en) 1992-05-26
PT99392A (pt) 1992-09-30
IE913814A1 (en) 1992-05-22

Similar Documents

Publication Publication Date Title
GR3019768T3 (en) N-substituted imidazol-2-one compounds for treatment of circulatory disorders
WO1992017469A3 (en) N-arylheteroarylalkyl imidazol-2-one compounds for treatment of circulatory disorders
DK0527851T3 (da) 1H-Substituerede 1,2,4-triazolforbindelser til behandling af kardiovaskulære forstyrrelser
DK0619819T3 (da) 1-Arylheteroarylalkyl-substituerede 1H-1,2,4-triazolforbindelser til behandling af kredsløbsforstyrrelser
DE69316224D1 (de) Chinuclidine derivate als squalen synthase inhibitoren
JP2003507342A5 (el)
EP0978515A3 (en) 1-(substituted phenyl)-4-biphenylmethyl-imidazol-2-one derivatives, their preparation and their use as angiotensin II antagonists
DE50006048D1 (de) Mono-und Dikaliumsalze von Azoverbindungen
FI940324A (fi) 1-(N-(halo-3-pyridyylimetyyli))-N-metyyliamino-1-alkyyliamino-2-nitroetyleenijohdannaiset kirppujen torjumiseksi kotieläimissä
DK0720598T3 (da) Phenoxyphenylcyclopentenyl-hydroxyurinstoffer
DK0664802T3 (da) N-Arylheteroarylalkyl-1-phenyl-imidazol-2-on-forbindelser til behandling af kredsløbssygdomme
DE59304359D1 (de) Ketorolac-Derivat mit wesentlich geringerer gastrointestinaler Reizung und Ulzeration
ES2064229A1 (es) Nuevas 1,2-dihidro-2-oxopiridinas de formula i.